Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Metabolix Inc (MBLX) -18.63% - decrease from $0.73 to $0.59
Metabolix, Inc. is an advanced biomaterials company. The Company is engaged in the business of developing and commercializing technologies for the production of polymers and chemicals in microbes and plants. It is focused on delivering solutions to the plastics industry. It has its operations in the microbial genetics, fermentation process engineering, chemical engineering, polymer science, plant genetics and botanical science. The Company offers three lines of products: biopolymers, bio-based chemicals and crop-based technologies. Its biopolymers include performance additives and functional biodegradation products, such as I6001, I6003rp, Mirel a-PHA copolymer modifier, Mirel Micropowders and Mirel P1003, F1005 for injection molding, among others. The Company's bio-based chemicals include Bio-based GBL/BDO and Bio-based Acrylic Acid. It also develops crop-based technology to co-produce renewable industrial chemicals with bioenergy in integrated bio refineries.
Metabolix Inc's price fell from 0.73 to 0.59 which is a 18.63% decrease.
https://zombiemarkets.com/articles/4d84e04b771e0ccedefdbc0f691bfd3c
the number of apri share shorted 2,473,300. the days to cover 8.7 days.
http://shortsqueeze.com/data.php?symbol=apri&submit=Short+Quote%99
also Aspire Capital will complete an initial purchase of 2,531,645 shares of common stock for proceeds of $1.0 million and has committed to purchase up to $6.0 million in additional shares of common stock over the next 24 months at prices based on the market price at the time of each sale. No warrants are associated with this agreement.
http://www.marketwatch.com/story/apricus-biosciences-enters-into-common-stock-purchase-agreement-with-aspire-capital-2016-07-06-8184854
if people hold on to this stock for one day and do not sell cheap, this stock will go .50 dollars or more very easily.
Aspire Capital will complete an initial purchase of 2,531,645 shares of common stock for proceeds of $1.0 million and has committed to purchase up to $6.0 million in additional shares of common stock over the next 24 months at prices based on the market price at the time of each sale. No warrants are associated with this agreement.
http://www.marketwatch.com/story/apricus-biosciences-enters-into-common-stock-purchase-agreement-with-aspire-capital-2016-07-06-8184854
The reason i am excited about imnp.
What Is Immune Pharma Doing With Ceplene?
Last week, shares of Immune Pharmaceuticals (IMNP) spiked in response to Jazz Pharma's acquisition of Celator Pharma for $1.5 billion. Celator is developing VYXEOS™, a liposome injection of cytarabine + daunorubicin for patients with high-risk (secondary) acute myeloid leukemia (AML). Back in March 2016, Celator announced Phase 3 data showing its formulation to be vastly superior to the standard of care regimen of cytarabine + daunorubicin, known as "7+3". In my opinion, VYXEOS will become the new standard of care for induction therapy in patients with high-risk AML. Jazz's take-out of Celator at nearly 100% premium has brought significant investor interest to the AML space.
Over the past few months, Immune has been highlighting new analyses of data with Ceplene® hinting at a potential path forward for the drug. Ceplene (histamine dihydrochloride) is administered in conjunction with low dose interleukin-2 (IL-2) for maintenance of remission in patients with AML following successful induction therapy. In theory, these are patients (or future patients) that achieve complete remission (CR) using VYXEOS but are ineligible for a "curative" bone marrow transplant (BMT) or still considered high-risk for relapse post-consolidation or post-BMT.
Investors briefly turned their enthusiasm for AML stocks to Immune early last week. Whether or not the spike in Immune Pharma shares was warranted is the subject of an article on Seeking-Alpha by Tom Mathies (see article HERE). In short, the author does not believe Ceplene has a viable future. However, I've studied some of the recent data that Immune has presented, including a new post hoc analysis from the Phase 3 trial and new data biomarker response analysis presented at the American Association for Cancer Research (AACR) Annual Meeting in April 2016, and I think there are some key points worth mentioning about Immune's Ceplene strategy.
http://www.bionapcfa.com/2016/06/what-is-immune-pharma-doing-with-ceplene.html
CURRENT IMMUNE PHARMACEUTICALS, INC. (NASDAQ:IMNP) PT MEANS STOCK IS WORTH ALMOST $3
http://reviewfortune.com/2016/07/21/current-immune-pharmaceuticals-inc-nasdaqimnp-pt-means-stock-is-worth-almost-3/
http://shortsqueeze.com/data.php?symbol=nept&submit=Short+Quote%99
total share shorted 2,107,100. day to cover this short is 96.7 days.
Nutraceutical revenues were $11.3 million for the three-month period ended May 31, 2016, versus $3.0 million in the first quarter ended May 31, 2015. Adjusted EBITDA2 was $1,138,000 for the current quarter, compared to a Non-IFRS operating loss of $3.2 million in the prior year. Consolidated revenues totalled $11.3 million for the three-month period ended May 31, 2016, up from $2.7 million for the quarter ended May 31, 2015.
any positive or semi positive news will shoot the price real real high. there are elements from the earning statement that indicate a good days is comming.
Date Open High Low Close Volume Adj
Close
2016/07/14 0.95 0.9853 0.9201 0.95 201,760 0.95
2016/07/13 0.99 0.99 0.9101 0.95 228,556 0.95
2016/07/12 1.11 1.11 0.94 0.96 337,826 0.96
2016/07/11 1.02 1.05 1.00 1.02 226,354 1.02
2016/07/08 1.01 1.04 0.9661 1.01 191,386 1.01
2016/07/07 1.00 1.04 1.00 1.01 51,023 1.01
2016/07/06 1.01 1.03 1.00 1.01 90,291 1.01
2016/07/05 1.03 1.05 1.00 1.00 86,905 1.00
2016/07/01 1.02 1.05 1.01 1.02 42,612 1.02
2016/06/30 1.05 1.08 1.00 1.02 29,581 1.02
2016/06/29 1.04 1.09 1.03 1.07 17,918 1.07
2016/06/28 1.02 1.05 1.02 1.04 12,517 1.04
2016/06/27 1.00 1.03 0.99 0.99 69,633 0.99
2016/06/24 1.03 1.03 1.00 1.00 59,919 1.00
2016/06/23 1.0516 1.08 1.03 1.03 13,396 1.03
The vix’s short term ETN is called tvix. It is one of the five vix futures tracking etn. Vix is a market volatility index. It is an option based measure of how much traders are willing to pay for stock portfolio insurance for 30 days. The vix tends to rise as s&p 500 falls and vice versa. This is also called fear index or market volatility index. When vix rallies, investor’s target the exchange traded products such barclay’s ipath s&P 500 short-terms exchange- traded notes which is tvix. The moves of vix comes ahead of central bank meeting and also events like Brexit vote. These sort of events tends to cause the fall of s&p 500 fall and thereby giving the rise of fear index or vix. And tvix is one of the tracking ETN for this index. But volatility is very transient and stays only a number of days and then stabilizes. When the s&m 500 stabilizes the vix falls. So the main point is this move is transient and is going to go away within a few days causing the extreme dip on prices of the tvix. If we look at the history of this stock we can very well assume that it is not a very permanent long lasting like other stocks.
Is It Time to Kill Fannie Mae? A $100 Billion Plan for the Mortgage Market
A plan to reform the mortgage finance industry by replacing Fannie Mae and Freddie Mac with a government-owned corporation offers insights into how presumptive Democratic presidential nominee Hillary Clinton might strengthen the housing market and guard against another financial crisis.
The latest proposal floated by a team of high-profile financial thinkers led by Gene Sperling, former director of the National Economic Council under both Presidents Bill Clinton and Barack Obama and an adviser to Hillary Clinton, would establish a corporation backed by more than $100 billion in investors’ money, according to Bloomberg News.The first phase of the proposal -- written by Sperling, Jim Parrott, Mark Zandi, Barry Zigas and Lew Ranieri, the granddaddy of mortgage-backed securities -- released in March says: “We are nearly seven years into recovery from a once-in-a-lifetime financial crisis … While much work has been done to address the flaws of this critical part of the nation’s economy, a major step remains: reforming Fannie Mae and Freddie Mac. These two enormously important yet flawed institutions endure in conservatorship while their regulator, the Federal Housing Finance Agency, admirably helps them tread water while pleading for direction from a paralyzed Congress.”
Fannie and Freddie don’t write mortgages; they buy them from lenders, back them and bundle them as securities. Because they play such a crucial role in the U.S. housing market, the government bailed out both government-sponsored enterprises (GSEs) in the financial crisis of 2008 to the tune of about $100 billion each and put them under the control of the Federal Housing Finance Agency.
The main thrust of the plan from Sperling and his colleagues is to merge Fannie and Freddie into a new entity, a government-owned corporation called the National Mortgage Reinsurance Corp. (NMRC), and transfer most of the risk inherent in the current system to private investors.
http://finance.yahoo.com/news/time-kill-fannie-mae-100-121500029.html
Stocks Intraday Alert: Orexigen Therapeutics, Inc. (NASDAQ:OREX), Tyson Foods, Inc. (NYSE:TSN)
http://stockznews.com/stocks-intraday-alert-orexigen-therapeutics-inc-nasdaqorex-tyson-foods-inc-nysetsn/
Orexigen Therapeutics, Inc. (NASDAQ:OREX) & Medtronic PLC (NYSE:MDT) Healthcare Stocks Alert
On Wednesday, Shares of Orexigen Therapeutics, Inc. (NASDAQ:OREX) gained 51.56% to $0.640. The share price is trading in a range of $0.45 – $0.65. The stock exchanged hands with 13.78 Million shares contrast to its average daily volume of 1.97 Million shares.
Orexigen Therapeutics, Inc. (OREX) declared that the United States District Court for the District of Delaware has issued a claim construction (Markman) ruling governing patent litigation brought by Orexigen and Takeda Pharmaceuticals against Actavis Laboratories FL, Inc., Andrx Corporation, Actavis Pharma, Inc., and Actavis Inc., collectively referred to as Actavis. The lawsuit was filed in response to an Abbreviated New Drug Application, or ANDA, filed by Actavis. In its application, Actavis seeks to market and sell a generic version of the presently approved dose of Contrave® (naltrexone HCl / bupropion HCl extended release) tablets preceding to the expiration of U.S. Patents listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. There are 10 Contrave patents listed in the Orange Book, the last of which expires in 2032.
Orexigen and Takeda filed the lawsuit on the basis that Actavis’ projected generic product infringes the Contrave patents. In a Markman ruling, also known as a claim construction ruling, the Court determines the meaning of disputed patent claim terms at issue in patent litigation. The Markman hearing for the Actavis litigation was held on May 24, 2016. In a June 6, 2016 Markman ruling, Judge Richard G. Andrews adopted Orexigen’s projected constructions for the majority of the disputed claim terms
http://wallstrt24.com/orexigen-therapeutics-inc-nasdaqorex-medtronic-plc-nysemdt-healthcare-stocks-alert/2413432/
Orexigen Stock Gains More than 50% on Markman Hearing
main points:
1) shares shot up 51.6% on a favorable Markman hearing in the company’s patent infringement lawsuit against Actavis
2)Orexigen is currently working on growing sales of the product. Following the acquisition of U.S. rights, the company is looking to adopt a targeted approach in growing Contrave sales. Orexigen will focus on differentiating Contrave from generic amphetamines and will work on improving the gross to net ratio through managed care and pharmacy discount strategies. Contrave should benefit from a more targeted sales effort. The company is planning a third quarter relaunch and expects Contrave to achieve market share of 10% - 11% by 2018. Orexigen is hiring 160 sales reps to promote the product.
https://www.zacks.com/stock/news/219826/orexigen-stock-gains-more-than-50-on-markman-hearing?cid=CS-MKTWTCH-HL-219826
OREX
5 Stocks Under $10 Set to Soar
https://www.thestreet.com/story/13602467/1/5-stocks-under-10-set-to-soar.html?puc=TSMKTWATCH&cm_ven=TSMKTWATCH
Orexigen Therapeutics, Inc. (NASDAQ:OREX)
Most Popular Healthcare Penny Stocks Among Hedge Funds
http://www.insidermonkey.com/blog/most-popular-healthcare-penny-stocks-among-hedge-funds-458697/
current fnma price in German market
Federal National Mortgage Association
FNM:GR
Stuttgart
2.06
EUR
0.00
-0.05%
As of 2:08 AM EDT 6/7/2016
http://www.bloomberg.com/quote/FNM:GR
headline contradicts the substance of this article.
This Fannie-Freddie resurrection needs to die
https://www.washingtonpost.com/opinions/this-fannie-freddie-resurrection-needs-to-die/2016/06/03/c8ad5162-282f-11e6-b989-4e5479715b54_story.html
first paragraph
"Consider the persistent non-solution to the zombie-like status of Fannie Mae and Freddie Mac known as “recap and release.” The plan is to return the two mortgage-finance giants to their pre-financial-crisis status as privately owned but “government-sponsored” enterprises."
the author acknowledge this is the plan, this is a very good plan for the share holder.
"But “no” is not an acceptable answer for the handful of Wall Street hedge funds that scooped up Fannie and Freddie’s beaten-down common stock for pennies a share after the bailout — and would realize a massive windfall if the government suddenly decided to let shareholders have access to company profits again."
This paragraph recognize the fact that there are private share holder for this enterprise.
therefore they are also the owner of this enterprise and profit needs to be distributed to
the share holder which they are fighting in the court.
"The latest iteration of recap and release is a hedge-fund-backed bill sponsored by Rep. Mick Mulvaney (R-S.C.), which would set Fannie and Freddie, unreformed, loose on the marketplace again and do so under terms wildly favorable to the hedge funds. Specifically, shareholders would be charged nothing for the government backing the entities would retain, supposedly to save scarce resources for the capital cushion.:"
this paragraph describes, there are member of congress who recognize the right of the
share holder and willing to argue that in the US congress for the share holder.
conclusion
"Fundamental reform would be a good idea, but you already know what happens to that."
this means the fundamental reform will never happen and it will eventually go its
pre crisis status which is privately owned but “government-sponsored” enterprises.
Dear sir i have some reservation about today's analysis.
this stock price is driven by the news of court since it is under government conservator ship and only court can do something to restore the right of the share holder under the auspices of fifth amendment right.
this is the historic analysis of the price range when there is a major news.
Historical Prices
Date Open High Low Close Volume Adj
Close
2014/04/02 4.04 4.0600 3.91 3.94 7,868,703 3.94
2014/04/01 3.98 4.14 3.92 3.98 23,517,061 3.98
2014/03/31 3.58 4.85 3.45 3.90 29,745,081 3.90
2014/03/28 3.65 3.65 3.55 3.57 9,100,259 3.57
2014/03/27 3.56 3.64 3.51 3.63 15,795,775 3.63
2014/03/26 3.41 3.53 3.35 3.46 9,480,030 3.46
2014/03/25 3.49 3.51 3.38 3.42 16,484,488 3.42
2014/03/24 3.59 3.60 3.42 3.52 13,993,285 3.52
2014/03/21 3.59 3.68 3.35 3.55 27,959,311 3.55
2014/03/20 3.45 3.62 3.38 3.58 25,682,365 3.58
2014/03/19 2.99 3.36 2.93 3.35 42,568,245 3.35
2014/03/18 3.74 3.74 2.99 3.06 107,748,324 3.06
2014/03/17 4.45 4.55 3.60 3.76 71,381,607 3.76
2014/03/14 3.92 4.26 3.83 4.13 49,235,853 4.13
2014/03/13 3.50 4.01 3.30 3.79 64,336,902 3.79
2014/03/12 3.30 3.79 3.20 3.54 124,279,931 3.54
2014/03/11 6.02 6.35 3.25 4.03 214,433,951 4.03
2014/03/10 5.48 5.85 5.30 5.82 30,338,555 5.82
2014/03/07 5.50 6.00 4.96 5.33 59,004,770 5.33
2014/03/06 4.96 5.45 4.90 5.25 47,636,054 5.25
2014/03/05 4.71 4.98 4.65 4.86 27,632,368 4.86
2014/03/04 4.6850 4.7700 4.63 4.70 18,770,428 4.70
2014/03/03 4.54 4.75 4.46 4.5600 34,714,986 4.5600
2014/02/28 4.71 4.80 4.40 4.78 37,640,072 4.78
2014/02/27 4.58 5.00 4.39 4.70 97,972,236 4.70
2014/02/26 4.21 4.51 3.94 4.47 81,809,568 4.47
please look at the march 11, 2014 price range. at that the time the only news was some hedge fund like fairholm's , Perry capital, Pershing sq hold the position of FNMA and they are suing the FHFA to restore the right of the share holder. This time, the magnitude of the news is huge. Delaware court already recognized FNMA as private enterprise which is a precursor for restoring the right of the share holder by nullifying the net worth sweep agreement. Attempt was made to derail the Delaware court process by filing Multi district judicial panel to consolidate all the cases in the Washington DC but it was denied by the panel paving the way for Delaware court to proceed. This is a huge news for the share holder. if the share price on march 11, 2014 was $ 6.02 this time it should be double if not triple. I am urging you to do analysis based on this historical price data. since you analysis is on the board and every body read it and many make decision how much price they want to spare based on your analysis, you prediction becomes very accurate most of the time. But this time news scale is very different and in favor of share holder.
Fannie Mae Price on German Market up 6.9%
https://finance.yahoo.com/q?s=fnm.sg
Fannie Mae Will Pay Treasury $919 Million After Reporting Profit
http://www.bloomberg.com/news/articles/2016-05-05/fannie-mae-will-pay-treasury-919-million-after-reporting-profit?cmpid=yhoo.headline
Freddie Mac’s First Quarter Loss Undermines Shareholder Lawsuits
http://blogs.wsj.com/moneybeat/2016/05/03/freddie-macs-first-quarter-loss-undermines-shareholder-lawsuits/?mod=yahoo_hs
You are right. originally i thought guru and fairholm funds words used interchangeably.
Fairholme Fund reduced its stake in Fannie Mae (FNMA) by 18.21% with an impact of -0.19% on the portfolio.
http://www.gurufocus.com/news/410633/fairholme-fund-sells-bank-of-america-leucadia-national
The guru reduced its stake in Fannie Mae (FNMA) by 18.21% with an impact of -0.19% on the portfolio
The fund reduced its stake in Federal Home Loan Mortgage Corp. (FMCC) by 7.30% with an impact of -0.12% on the portfolio.
In this article there is no mention of Fannie Mae for once.
https://finance.yahoo.com/q?s=fnm.sg
Sorry never thought it could be EURO. thanks for pointing it out.
FNMA in German market
FANNIE MAE (FNM.SG) -Stuttgart
Watchlist
1.4940 Down 0.4150(21.74%) 4:20AM EDT
Prev Close: 1.86
Open: 1.50
Bid: 1.4940 x 3000000
Ask: 1.5320 x 3000000
1y Target Est: N/A
Beta: N/A
Next Earnings Date: N/A
Day's Range: 1.4940 - 1.4950
52wk Range: 0.90 - 2.62
Volume: 500
Avg Vol (3m): 30,434
Market Cap: N/A
P/E (ttm): N/A
EPS (ttm): N/A
Div & Yield: N/A (N/A)
Quotes delayed, except where indicated otherwise. Currency in EUR.
In German market now
FANNIE MAE (FNM.SG) -Stuttgart
Watchlist
1.52 Down 0.39(20.38%) 7:32AM EDT
Prev Close: 1.86
Open: 1.53
Bid: 1.52 x 3000000
Ask: 1.54 x 1000000
1y Target Est: N/A
Beta: N/A
Next Earnings Date: N/A
Day's Range: 1.52 - 1.54
52wk Range: 0.90 - 2.62
Volume: 8,500
Avg Vol (3m): 30,399
Market Cap: N/A
P/E (ttm): N/A
EPS (ttm): N/A
Div & Yield: N/A (N/A)
If the Perry capital court case is denied in any moment, which has a higher probability this stock is going to be comeback to less than a dollar. Investors Unite or Pagliara or Hamish Hume has zero influence on the court decision. Government has huge influence on the court decision. This is why you see all the institutional investor are not buying just watching.
These are the same old 7 document. There are no new documents
Fannie, Freddie Shareholder Lawsuit Looks Less Good When You Read The Law
http://dealbreaker.com/2016/04/fannie-freddie-shareholder-lawsuit-looks-less-good-when-you-read-the-law/
Judge Lambarth dismissed the Perry capital case based on one congressional provision. and that is Congress mandated the FHFA to take any action for the sustainibility of the Fannie Mae and protection of the taxpayer money. FHFA has so far side aside some 258 billions to inject these two mortgage giant for protection if needed and did the net sweep agreement for the protection of tax payer interest. Congressional provision does not address any protection of the shareholder's interest. Congressional provision also states that any action FHFA or treasury takes to safeguard this two key provision is not the subject of judicial review. And this is the most key factor judge lamberth took into account in ruling the Perry capital case. "Not the subject of judicial review " this key factor is also going to determine the current appeal process and there for deny the revival of this case.